ITEOS THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.72 USD | -1.76% |
|
+35.82% | +52.69% |
Presentation Operator MessageOperator (Operator)Good morning, and welcome to the iTeos Therape...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes three clinical-stage programs targeting novel, validated immuno-oncology pathways. Its lead antibody product candidate, belrestotug, also known as EOS-448/GSK4428859A, is an antagonist of TIGIT, an immune checkpoint with multiple mechanisms of action. Its advanced program is inupadenant, also known as EOS-850, a next-generation adenosine 2A receptor (A2AR) antagonist tailored to overcome the specific adenosine-mediated immunosuppression found in the tumor microenvironment. Its program to initiate clinical trials is EOS-984, a potentially first-in-class small molecule focused on a new mechanism in the adenosine pathway by targeting equilibrative nucleoside transporter 1 (ENT1), a dominant transporter of adenosine on lymphocytes involved in T cell metabolism.
Calendar
2024-06-11
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.72
USD
Average target price
35
USD
Spread / Average Target
+109.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +52.69% | 634M | |
| +5.33% | 111B | |
| +12.11% | 105B | |
| -12.56% | 22.34B | |
| -3.70% | 21.93B | |
| -6.03% | 18.59B | |
| -35.21% | 18.12B | |
| -10.86% | 16.96B | |
| +5.10% | 13.7B | |
| +37.57% | 12.45B |
- Stock Market
- Equities
- ITOS Stock
- News iTeos Therapeutics, Inc.
- Transcript : iTeos Therapeutics, Inc. - Special Call
